IRVINE, Calif., Sept. 12 /PRNewswire-FirstCall/ -- Masimo Corporation
(Nasdaq: MASI), the inventor of Pulse CO-Oximetry and Read-Through Motion and
Low Perfusion pulse oximetry, today announced it will release second quarter
financial results for the period ended June 30, 2007 after the market closes
on Wednesday, September 19, 2007.
A conference call to review the results will begin at 2:00 p.m. PT
(5:00 p.m. ET) and will be hosted by Joe E. Kiani, Chairman and Chief
Executive Officer, and Mark P. de Raad, Executive Vice President & Chief
Financial Officer.
A live web cast of the conference call will be available online from the
investor relations page of the Company's corporate web site at www.masimo.com.
The dial-in numbers are (866) 700-7441 for domestic callers and (617) 213-8839
for international callers. The reservation number for both dial-in numbers is
11107851. After the live web cast, the call will remain available on
Masimo's web site through October 19, 2007. In addition, a telephonic replay
of the call will be available until October 3, 2007. The replay dial-in
numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for
international callers. Please use reservation code 65525346.
About Masimo
Masimo develops innovative monitoring technologies that significantly
improve patient care-helping solve "unsolvable" problems. In 1995, the company
debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET,
and with it virtually eliminated false alarms and increased pulse oximetry's
ability to detect life-threatening events. More than 100 independent and
objective studies have confirmed that Masimo SET technology allows clinicians
to accurately monitor blood oxygen saturation in critical care situations.
Our Masimo SET platform has significantly addressed many of the previous
technology limitations, has substantially contributed to improved patient
outcomes and has been referred to by several industry sources as the gold
standard in pulse oximetry. In 2005, Masimo introduced Masimo Rainbow SET
Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level
of carbon monoxide and methemoglobin in the blood, allowing early detection
and treatment of potentially life-threatening conditions. Founded in 1989,
Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications."
Additional information about Masimo and its products may be found at
www.masimo.com.
SOURCE Masimo Corporation
CONTACT: Investors, Mark P. de Raad, Executive Vice President and Chief
Financial Officer, +1-949-297-7041, mderaad@masimo.com, or Media, Tom McCall,
V.P. Marketing Communications, +1-949-297-7075, tmccall@masimo.com, both of
Masimo Corporation
Web site: http://www.masimo.com